132. Rowell NP, O’Rourke N P. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane
Database Syst Rev 2004;(4):CD002140.
133. Martini N, Kris M, Flehinger B, et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer:
the Sloan- Kettering experience with 136 patients. Ann Thorac Surg 1993;55(6):1365–1373.
134. Sugarbaker DJ, Herndon J, Kohman LJ, et al. Results of cancer and leukemia group B protocol
8935 A multiinstitutional phase II trimodality trial for stage IIIa (N2) non-small-cell lung cancer. J
Thorac Cardiovasc Surg 1995;109(3):473–485.
135. Faber L, Kittle C, Warren W, et al. Preoperative chemotherapy and irradiation for stage III nonsmall cell lung cancer. Ann Thorac Surg 1989;47(5):669–675.
136. Weiden P, Piantadosi S. Preoperative chemotherapy (cisplatin and fluorouracil) and radiation
therapy in stage III non-small-cell lung cancer: a phase II study of the Lung Cancer Study Group. J
Natl Cancer Inst 1991;83(4):266–273.
2272
137. Strauss G, Herndon J, Sherman D, et al. Neoadjuvant chemotherapy and radiotherapy followed by
surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group
B phase II study. J Clin Oncol 1992;10(8):1237–1244.
138. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy
followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of
Southwest Oncology Group phase II study 8805. J Clin Oncol 1995;13(8):1880–1892.
139. Taylor NA, Liao ZX, Cox JD, et al. Equivalent outcome of patients with clinical Stage IIIA nonsmall-cell lung cancer treated with concurrent chemoradiation compared with induction
chemotherapy followed by surgical resection. Int J Rad Oncol Biol Phys 2004;58(1):204–212.
140. Albain KS, Scott CB, Rusch VR, et al. PL-4 Phase III study of concurrent chemotherapy and full
course radiotherapy (CT/RT) versus CT/RT induction followed by surgical resection for stage
IIIA(pN2) non-small cell lung cancer (NSCLC): first outcome analysis of North American Intergroup
trial 0139 (RTOG 93–09). Lung Cancer 2003;41(Supplement 2):S4.
141. Thomas M, Rübe C, Hoffknecht P, et al. Effect of preoperative chemoradiation in addition to
preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol
2008;9(7):636–648.
142. Albain K, Rusch V, Crowley J, et al. Long-term survival after concurrent cisplatin/etoposide (PE)
plus chest radiotherapy (RT) followed by surgery in bulky, stages IIIA(N2) and IIIB non-small cell
lung cancer (NSCLC): 6-year outcomes from Southwest Oncology Group Study 8805. Proc of the Am
Soc Clin Oncol 1999;18:467A.
143. Burfeind WR Jr., D’Amico TA, Toloza EM, et al. Low morbidity and mortality for bronchoplastic
procedures with and without induction therapy. Ann Thorac Surg 2005;80(2):418–421.
144. Adelstein DJ, Rice TW, Rybicki LA, et al. Accelerated hyperfractionated radiation, concurrent
paclitaxel/cisplatin chemotherapy and surgery for stage III non-small cell lung cancer. Lung Cancer
2002;36(2):167—174.
145. Weil MD, Roach I, Mack, Pickett B, et al. 3D conformal radiotherapy in the sagittal plane for
centrally located thoracic tumors. Med Dosim 1995;20(1):11–14.
146. Hayman JA, Martel MK, Ten Haken RK, et al. Dose escalation in non-small-cell lung cancer using
three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol
2001;19(1):127–136.
147. Pancoast H. Superior pulmonary sulcus tumor: tumor characterized by pain, Horner’s syndrome,
destruction of bone and atrophy of hand muscles. JAMA 1932;99:1391–1396.
148. Vallieres E, Kraut M, Thomas C. Pancoast (superior sulcus) neoplasms. Curr Prob Canc
2003;27(2):81–104.
149. Shaw R, Paulson D, Kee JJ. Treatment of the superior sulcus tumor by irradiation followed by
resection. Ann Surg 1961;154:29–40.
150. Rusch V, Parekh K, Leon L, et al. Factors determining outcome after surgical resection of T3 and T4
lung cancers of the superior sulcus. J Thorac Cardiovasc Surg 2000;119(6):1147–1153.
151. Detterbeck FC. Pancoast (superior sulcus) tumors. Ann Thorac Surg 1997;63(6):1810–1818.
152. Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for superior
sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416
(Intergroup Trial 0160). J Clin Oncol 2007;25(3):313–318.
153. Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed
criteria for large-cell neuroendocrine carcinoma. an ultrastructural, immunohistochemical, and flow
cytometric study of 35 cases. Am J Surg Pathol 1991;15(6):529–553.
154. Vuitch F, Sekido Y, Fong K, et al. Neuroendocrine tumors of the lung. pathology and molecular
biology. Chest Surg Clin N Am 1997;7(1):21–47.
155. McCaughan B, Martini N, Bains M. Bronchial carcinoids. review of 124 cases. J Thorac Cardiovasc
Surg 1985;89(1):8–17.
156. Cañizares MA, Matilla JM, Cueto A, et al. Atypical carcinoid tumours of the lung: prognostic factors
and patterns of recurrence. Thorax 2014;69(7):648–653.
157. García-Yuste M, Matilla JM, Cueto A, et al. Typical and atypical carcinoid tumours: analysis of the
experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung. Eur J
Cardiothorac Surg 2007;31(2):192–197.
2273
158. Naalsund A, Rostad H, Str⊘m EH, et al. Carcinoid lung tumors – incidence, treatment and outcomes:
a population-based study. Eur J Cardiothorac Surg 2011;39(4):565–569.
159. Jiang S-X, Kameya T, Shoji M, et al. Large cell neuroendocrine carcinoma of the lung: a histologic
and immunohistochemical study of 22 cases. Am J Surg Pathol 1998;22(5):526–537.
160. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors
with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J
Surg Pathol 1998;22(8):934–944.
161. Zacharias J, Nicholson AG, Ladas GP, et al. Large cell neuroendocrine carcinoma and large cell
carcinomas with neuroendocrine morphology of the lung: prognosis after complete resection and
systematic nodal dissection. Ann Thorac Surg 2003;75(2):348–352.
162. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the
United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results
database. J Clin Oncol 2006;24(28):4539–4544.
163. Micke P, Faldum A, Metz T, et al. Staging small cell lung cancer: Veterans Administration Lung
Study Group versus International Association for the Study of Lung Cancer—what limits limited
disease?Lung Cancer 2002;37(3):271–276.
164. Stahel RA, Ginsberg R, Havemann K, et al. Staging and prognostic factors in small cell lung cancer:
a consensus report. Lung Cancer 1989; 5(4–6):119–126.
165. Shepherd FA. The role of chemotherapy in the treatment of small cell lung cancer. Chest Surg Clin N
Am 1997;7(1):113–133.
166. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung
cancer. N Engl J Med 1992;327(23):1618–1624.
167. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited- stage
small-cell carcinoma of the lung? a meta-analysis. J Clin Oncol 1992;10(6):890–895.
168. Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation
therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol
2004;22(23):4837–4845.
169. Albain KS, Crowley JJ, LeBlanc M, et al. Determinants of improved outcome in small-cell lung
cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol
1990;8(9):1563–1574.
170. Inoue M, Miyoshi S, Yasumitsu T, et al. Surgical results for small cell lung cancer based on the new
TNM staging system. Ann Thorac Surg 2000;70(5):1615–1619.
171. van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet
2011;378(9804):1741–1755.
172. Kreisman H, Wolkove N, Quoix E. Small cell lung cancer presenting as a solitary pulmonary nodule.
Chest 1992;101(1):225–231.
173. Brock MV, Hooker CM, Syphard JE, et al. Surgical resection of limited disease small cell lung
cancer in the new era of platinum chemotherapy: its time has come. J Thorac Cardiovasc Surg
2005;129(1):64–72.
174. Shepherd FA, Evans WK, Feld R, et al. Adjuvant chemotherapy following surgical resection for
small-cell carcinoma of the lung. J Clin Oncol 1988;6(5):832–838.
175. Le Pechoux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose prophylactic cranial
irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after
chemotherapy and thoracic radiotherapy (PCI 99–01, EORTC 22003–08004, RTOG 0212, and IFCT
99–01): a randomised clinical trial. Lancet Oncol 2009;10(5):467–474.
176. Shah S, Thompson J, Goldstraw P. Results of operation without adjuvant therapy in the treatment
of small cell lung cancer. Ann Thorac Surg 1992; 54(3):498–501.
177. Shepherd F, Ginsberg R, Patterson G, et al. Is there ever a role for salvage operations in limited
small-cell lung cancer? J Thorac Cardiovasc Surg 1991;101(2):196–200.
178. Lad T, Piantadosi S, Thomas P, et al. A prospective randomized trial to determine the benefit of
surgical resection of residual disease following response of small cell lung cancer to combination
chemotherapy. Chest 1994;106(6):320S–323S.
179. Inoue H, Iwasaki M, Ogawa J, et al. Surgical resection of a second primary lung carcinoma in a
survivor of small cell carcinoma. Ann Thorac Surg 1993;56(5):1160–1161.
2274
180. Heitmiller R, Mathisen D, Ferry J, et al. Mucoepidermoid lung tumors. Ann Thorac Surg
1989;47(3):394–399.
181. Moran CA. Primary salivary gland-type tumors of the lung. Semin Diagn Pathol 1995;12(2):106–122.
182. Webb BD, Walsh GL, Roberts DB, et al. Primary tracheal malignant neoplasms: the University of
Texas MD Anderson Cancer Center experience. J Am Coll Surg 2006;202(2):237–246.
183. Gaissert HA, Grillo HC, Shadmehr MB, et al. Long-term survival after resection of primary adenoid
cystic and squamous cell carcinoma of the trachea and carina. Ann Thorac Surg 2004;78(6):1889–
1897.
184. Maziak DE, Todd TR, Keshavjee SH, et al. Adenoid cystic carcinoma of the airway: thirty-two-year
experience. J Thorac Cardiovasc Surg 1996; 112(6):1522–1532.
185. Chin H, DeMeester T, Chin R, et al. Endobronchial adenoid cystic carcinoma. Chest
1991;100(5):1464–1465.
186. Miller DL, Allen MS. Rare pulmonary neoplasms. Mayo Clin Proc 1993;68(5):492–498.
187. Berho M, Moran CA, Suster S. Malignant mixed epithelial/mesenchymal neoplasms of the lung.
Semin Diagn Pathol 1995;12(2):123–139.
188. Barney JD, Churchill ED. Adenocarcinoma of the kidney with metastases to the lung cured by
nephrectomy and lobectomy. J Urol 1939;42:269–276.
189. Clagett OT, Woolner LB. Surgical treatment of solitary metastatic pulmonary lesion. Med Clin North
Am 1964;48:939–943.
190. Mountain CF, McMurtrey MJ, Hermes KE. Surgery for pulmonary metastasis: a 20-year experience.
Ann Thorac Surg 1984;38(4):323–330.
191. Martini N, Huvos AG, Mike V, et al. Multiple pulmonary resections in the treatment of osteogenic
sarcoma. Ann Thorac Surg 1971;12(3):271–280.
192. Crow J, Slavin G, Kreel L. Pulmonary metastasis: a pathologic and radiologic study. Cancer
1981;47(11):2595–2602.
193. Heitmiller RF, Marasco WJ, Hruban RH, et al. Endobronchial metastasis. J Thorac Cardiovasc Surg
1993;106(3):537–542.
194. Loehe F, Kobinger S, Hatz RA, et al. Value of systematic mediastinal lymph node dissection during
pulmonary metastasectomy. Ann Thorac Surg 2001; 72(1):225–229.
195. Ercan S, Nichols FC III, Trastek VF, et al. Prognostic significance of lymph node metastasis found
during pulmonary metastasectomy for extrapulmonary carcinoma. Ann Thorac Surg
2004;77(5):1786–1791.
196. Johnson H Jr., Fantone J, Flye MW. Histological evaluation of the nodules resected in the
treatment of pulmonary metastatic disease. J Surg Oncol 1982;21(1):1–4.
197. Pastorino U, Buyse M, Friedel G, et al. Long-term results of lung metastasectomy: prognostic
analyses based on 5206 cases. J Thorac Cardiovasc Surg 1997;113(1):37–49.
198. McCormack PM, Ginsberg KB, Bains MS, et al. Accuracy of lung imaging in metastases with
implications for the role of thoracoscopy. Ann Thorac Surg 1993;56(4):863–865.
199. Pastorino U, Veronesi G, Landoni C, et al. Fluorodeoxyglucose positron emission tomography
improves preoperative staging of resectable lung metastasis. J Thorac Cardiovasc Surg
2003;126(6):1906–1910.
200. Deleyiannis FW, Thomas DB. Risk of lung cancer among patients with head and neck cancer.
Otolaryngol Head Neck Surg 1997;116(6):630–636.
201. Robert JH, Ambrogi V, Mermillod B, et al. Factors influencing long-term survival after lung
metastasectomy. Ann Thorac Surg 1997;63(3):777–784.
202. Rusch VW. Pulmonary metastasectomy. current indications. Chest 1995;107(6):322S–331S.
203. Girard P, Baldeyrou P, Le Chevalier T, et al. Surgery for pulmonary metastases. who are the 10-
year survivors? Cancer 1994;74(10):2791–2797.
204. McCormack P. Surgical resection of pulmonary metastases. Semin Surg Oncol 1990;6(5):297–302.
205. La Quaglia MP. Osteosarcoma. specific tumor management and results. Chest Surg Clin N Am
1998;8(1):77–95.
206. Singletary SE, Walsh G, Vauthey JN, et al. A role for curative surgery in the treatment of selected
patients with metastatic breast cancer. Oncologist 2003;8(3):241–251.
2275
207. Friedel G, Pastorino U, Ginsberg RJ, et al. Results of lung metastasectomy from breast cancer:
prognostic criteria on the basis of 467 cases of the international registry of lung metastases. Eur J
Cardiothorac Surg 2002;22(3):335–344.
208. Feldman DR, Bosl GJ, Sheinfeld J, et al. Medical treatment of advanced testicular cancer. JAMA
2008;299(6):672–684.
209. Liu D, Abolhoda A, Burt ME, et al. Pulmonary metastasectomy for testicular germ cell tumors: a 28-
year experience. Ann Thorac Surg 1998;66(5):1709–1714.
210. Kesler KA, Rieger KM, Hammoud ZT, et al. A 25-year single institution experience with surgery for
primary mediastinal nonseminomatous germ cell tumors. Ann Thorac Surg 2008;85(2):371–378.
211. Kesler KA, Wilson JL, Cosgrove JA, et al. Surgical salvage therapy for malignant intrathoracic
metastases from nonseminomatous germ cell cancer of testicular origin: analysis of a singleinstitution experience. J Thorac Cardiovasc Surg 2005;130(2):408–415.
212. Putnam JB Jr, Suell DM, Natarajan G, et al. Extended resection of pulmonary metastases: is the risk
justified? Ann Thorac Surg 1993;55(6):1440–1446.
213. Koong HN, Pastorino U, Ginsberg RJ. Is there a role for pneumonectomy in pulmonary metastases?
Ann Thorac Surg 1999;68(6):2039–2043.
214. Bains MS, Ginsberg RJ, Jones W 2nd, et al. The clamshell incision: an improved approach to
bilateral pulmonary and mediastinal tumor. Ann Thorac Surg 1994;58(1):30–32.
215. Liu H, Lin P, Hsieh M, et al. Application of thoracoscopy for lung metastases. Chest
1995;107(1):266–268.
216. Petersen RP, Hanish SI, Haney JC, et al. Improved survival with pulmonary metastasectomy: an
analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg
2007;133(1):104–110.
217. Gossot D, Radu C, Girard P, et al. Resection of pulmonary metastases from sarcoma: can some
patients benefit from a less invasive approach? Ann Thorac Surg 2009;87(1):238–243.
218. Briccoli A, Rocca M, Salone M, et al. Resection of recurrent pulmonary metastases in patients with
osteosarcoma. Cancer 2005;104(8):1721–1725.
219. Kandioler D, Kromer E, Tuchler H, et al. Long-term results after repeated surgical removal of
pulmonary metastases. Ann Thorac Surg 1998;65(4):909–912.
220. Liu D, Labow DM, Dang N, et al. Pulmonary metastasectomy for head and neck cancers. Ann Surg
Oncol 1999;6(6):572–578.
221. Arrigoni MG, Woolner LB, Bernatz PE, et al. Benign tumors of the lung. a ten-year surgical
experience. J Thorac Cardiovasc Surg 1970;60(4):589–599.
222. Oldham HN Jr. Benign tumors of the lung and bronchus. Surg Clin North Am 1980;60(4):825–834.
223. Hansen CP, Holtveg H, Francis D, et al. Pulmonary hamartoma. J Thorac Cardiovasc Surg
1992;104(3):674–678.
224. Kavolius JP, Mastorakos DP, Pavlovich C, et al. Resection of metastatic renal cell carcinoma. J Clin
Oncol 1998;16(6):2261–2266.
225. McCormack PM, Burt ME, Bains MS, et al. Lung resection for colorectal metastases. 10-year results.
Arch Surg 1992;127(12):1403–1406.
226. Billingsley KG, Burt ME, Jara E, et al. Pulmonary metastases from soft tissue sarcoma: analysis of
patterns of diseases and postmetastasis survival. Ann Surg 1999;229(5):602–610.
2276
Chapter 80
Non-Neoplastic Thoracic Disease
Rishindra M. Reddy
Key Points
1 Surgical intervention for chest wall tumors depends on the type of lesion and goals of surgery
(resection vs. diagnosis). Reconstruction varies depending on the size of the defect and location on
the chest wall.
2 Thoracic outlet syndrome (TOS) may be arterial, venous, or neurogenic. Neurogenic TOS is the most
difficult to diagnose and surgery for this should be performed in high-volume centers.
3 The primary treatment for a lung abscess is antibiotic therapy.
4 Hemoptysis can be life-threatening from suffocation due to a low volume of blood in the lungs, not
from blood volume loss requiring transfusion.
5 Primary spontaneous pneumothoraces will recur in only 30% of patients after initial treatment.
When they recur, the treatment should include a thoracoscopic evaluation and possible pleurodesis.
6 Transudative pleural effusions should be treated medically, while exudative effusions may need
more intervention. One-quarter of pleural effusions in a community hospital are due to malignancy.
7 Empyema is a part of a spectrum of disease that may be treated early on with drainage alone, but
may require debridement and decortication in more advanced cases.
8 Complications of tracheostomies are usually due to improper placement of the tracheostomy on the
trachea (below the 3rd ring, risking a tracheoinnominate fistula) or to the use of high pressures in
the cuff of the tracheostomy (causing ischemia and long-term stenosis)
9 Mediastinitis is life-threatening and warrants immediate evaluation, antibiotic therapy, and surgical
drainage.
INTRODUCTION
This chapter is meant as resource for the general surgery community and surgery residents with regard
to pathology in the chest. We will cover a wide variety of topics including most noncardiac congenital
disease processes in the thorax.
CHEST WALL ANATOMY
The chest wall is the musculoskeletal structure that contains and protects the structures of the upper
trunk or thorax. There are two openings to the thorax, the superior aperture, or the thoracic inlet, and
the inferior aperture which leads to the abdominal cavity. The head and arms connect to the
intrathoracic structures via the inlet, whereas the diaphragm separates the thoracic and abdominal
cavities at the inferior aperture. The inferior vena cava, esophagus, and aorta all travel to the abdomen
through the diaphragm at levels T8, T10, and T12, respectively.
The sternum, commonly known as the breast bone, is comprised of three parts, the manubrium, the
body, and the xiphoid. The manubrium attaches to the clavicles and the first costal cartilages. The
sternal angle where the manubrium and body connect is called the angle of Louis and is an important
landmark. The second ribs attach to the sternum at this angle and they allow one to count the ribs from
this point down, as the first ribs are not palpable. The body of the sternum contains articular facets for
ribs 2 to 7 and connects to the cartilaginous xiphoid inferiorly. The xiphoid may be bifid and will
eventually ossify in older adults (Fig. 80-1).
The ribs are split into two groups; the upper 7 pairs are the true ribs, with articulations to the
sternum, while the lower 5 pairs are the false ribs. Ribs 8, 9, and 10 connect to each other and the
2277
No comments:
Post a Comment
اكتب تعليق حول الموضوع